All News

WIR.large_.jpg (keep)

RheumNow Podcast – The Future of JAKs (6.5.20)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Corona.COVID_.jpg

EULAR and ACR COVID19 Guidelines: Similarities Provide Reassurance

d Rachel Tate, DO

In difficult times, it's reassuring to reflect on the similarities that bring us together. In the case of the EULAR and ACR COVID19 guidelines as discussed at #EULAR2020 by Drs.

Read Article
mask.cough_.URI_.jpg

Preventing COVID - Masks, Meters and Eyewear

d Jack Cush, MD

A Lancet systematic review and meta-analysis provides the basis for physical distancing and the value of making as measures to prevent infection with coronavirus 2 (SARS-CoV-2) or COVID-19.

The analysis included 172 observational studies, no randomised controlled trials and 44 relevant comparative studies involving 25 697 patients. 

Read Article
infx.pneumonia.jpg

Hydroxychloroquine Postexposure Prophylaxis for COVID-19 Fails

d Jack Cush, MD

NEJM has reported that the use of hydroxychloroquine did not prevent symptomatic COVID-19 infection when used within 4 days after SARS-CoV-2 exposure.



Currently for persons who are COVID exposed, the standard of care is quarantine and there is no known preventative therapy.

Read Article
Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than other diseases such as RA and chloroquine has a far higher risk of retinal toxicity OP0333 #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/ZzRy3po4yw

Links:

Janet Pope Janetbirdope ( View Tweet)

Serum calprotectin as a biomarker in ANCA-associated vasculitis is enticing, and not just during induction: during maintenance following remission, it might predict relapse and renal decline independently of disease characteristics MAINRITSAN data OP0031 #EULAR2020 @RheumNow https://t.co/ItI0BPGrUX
David Liew drdavidliew ( View Tweet)
#EULAR2020 OP0167 Results are finally in!! MMF can be safely w/drawn in quiescent SLE: prospect RCT (nonblinded) 102 pts. MMF tapered over 12 weeks, f/u 60 weeks; no sig diff for flares in pts who stopped MMF vs. maintained; pts who cont MMF had ⬆️ minor infections. @rheumnow https://t.co/bOnuEBLis9
k dao KDAO2011 ( View Tweet)
So #EULAR2020 was meant to be in Germany, and I was meant to go. I am currently not in Germany. Germany can come to me! Just getting into the #EULAR2020goesvirtual spirit @RheumNow https://t.co/RxeTwunR0K
David Liew drdavidliew ( View Tweet)

When starting IV Pegloticase in #Gout, Do you start a DMARD too? #EULAR2020

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! The Future of JAKs. Watch it here>> https://t.co/Ot483P99RB or listen to the Podcast on iTunes>>https://t.co/FHJv01AAbC or on SoundCloud>>https://t.co/1ImZzhb0mS

Links:

Dr. John Cush RheumNow ( View Tweet)

Tofacitinib shown to be effective (vs Placebo) in 225 Polyarticular JIA (included some ERA & PsA). with less flares (29 vs 53%) and higher JCR30 responses (71 vs 47%) @6mos #EULAR2020 #OP0281 https://t.co/3BnZeB4ROr https://t.co/4pTLbTtBdN

Links:

Dr. John Cush RheumNow ( View Tweet)
CDC guidelines for Rx of Latent Tuberculosis; Preferred: A) 3 months of once-weekly INH plus rifapentine (3HP); B) 4 months of daily rifampin (4R); C) 3 months of daily INH plus rifampin (3HR) - Shorter, safer, effective with higher completion rates. https://t.co/a2iZczFTP2

Links:

Dr. John Cush RheumNow ( View Tweet)

Lancet has issued an almost retraction - an "Expression of Concern" alerting readers that many have voiced scientific concerns about the Lancet HCQ/CQ paper w/ more deaths. MORE DEATHS COULD HAVE BEEN FROM THE DRUGS OR THE DRUGS BEING USED IN SICKER PTS https://t.co/saoE32qpuF

Links:

Dr. John Cush RheumNow ( View Tweet)

Open label, uncontrolled study shows that background use of azathioprine (2mg/kg) in Pegloticase treated refractory gout patients was partly effective - 6/12 completed, 2 still on Rx, 2 PEG ineffective and 2 side effx #EULAR2020 #Gout Abst#THU0410 https://t.co/APZRPCQUFg https://t.co/Nfsq4QjyA5

Links:

Dr. John Cush RheumNow ( View Tweet)
Use of HCQ was not associated with development of ❤️Heart Failure in patients with RA. There was no statistically significant association between the cumulative dose of HCQ & HF. A good study from #MayoClinic. #EULAR2020 #eular20 https://t.co/yG03e0TAcV
Mario Pompermayer, MD pompermarioMD ( View Tweet)
ILD RA has more hospital admissions. Occurs in 14% of RA. Increased mortality. Serious complication of RA @eular_org @RheumNow @CRASCRRheum @earlyarthritis #EULAR2020 OP0039 https://t.co/2N3tulzq3R

Links:

Janet Pope Janetbirdope ( View Tweet)

Nice surprise as IL23 Guselkumab works not only in PsA but axial PsA. Another Rx option also presented at @eular_org #EULAR2020 @CRASCRRheum @earlyarthritis https://t.co/dUqqagzbeC

Links:

Janet Pope Janetbirdope ( View Tweet)

Can machine learning/AI predict who will respond & get remission in RA prior to bDMARD? High dose steroids, older age high ESR long disease duration worse outcomes but not same for each drug. OP0023 @eular_org #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/oNXDVQbzMC
Janet Pope Janetbirdope ( View Tweet)
We're still poor at estimating the chance of remission with bDMARDs for individuals w RA - but maybe AI can help provide them with a personalised prediction of their chances of success? Remission predicted here w 57-73% accuracy. Korean national data OP0023 #EULAR2020 @RheumNow https://t.co/zNw3j5VZni
David Liew drdavidliew ( View Tweet)
Tocilizumab in GCA - three year data from GiACTA on steroid exposure and time to flare: - steroid-sparing benefit persists in both new-onset and relapsing disease - in avoiding flares, benefit for weekly dosing in both new-onset and relapsing disease OP0027 #EULAR2020 @RheumNow https://t.co/tGU6ayglHW
David Liew drdavidliew ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×